Mycoril (Clotrimazole)

Clotrimazole blocks the fungal enzyme lanosterol 14α‑demethylase, which is essential for converting lanosterol to ergosterol. By inhibiting ergosterol synthesis, the drug disrupts the fungal cell membrane, increasing its permeability and halting fungal growth and replication.

The specific dosing regimen for Mycoril is determined by the prescribing healthcare professional. Typically, a thin layer is applied to the affected area once to twice daily, and treatment continues for 2‑4 weeks or until the infection has cleared, as directed by the prescriber.

Safety data for clotrimazole in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and this decision should be made in consultation with a qualified healthcare provider.

To order Mycoril, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The team then replies with pricing, availability, shipping details and any necessary import documentation.

Mycoril (clotrimazole) is a broad‑spectrum topical imidazole, offering convenient over‑the‑counter use for many skin fungal infections. Compared with allylamine agents such as terbinafine, clotrimazole has a slightly slower onset but is effective against both dermatophytes and yeasts, making it a versatile first‑line choice for mixed infections.

Mycoril should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct sunlight, and ensure the cap is tightly closed after each use to maintain stability and potency.

Apply a thin layer of Mycoril to clean, dry skin in the affected area. Gently rub it in until it disappears, usually once or twice daily as advised by a healthcare professional. Avoid covering the treated skin with occlusive dressings unless instructed, and wash hands after application.

While most users experience only mild local irritation, serious adverse reactions can include allergic contact dermatitis, severe skin reactions such as Stevens‑Johnson syndrome, and, rarely, systemic toxicity affecting liver or blood cells when large skin areas are treated. Seek immediate medical attention if any severe rash, blistering or systemic symptoms develop.

Mycoril should be avoided in individuals with known hypersensitivity to clotrimazole or any component of the formulation. It is also not recommended for use on extensive broken skin, in patients with severe liver disease, or in pregnant or breastfeeding women unless the potential benefit outweighs the risk and a clinician approves its use.